Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | thyroid hormone receptor, beta | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Brugia malayi | photoreceptor-specific nuclear receptor | thyroid hormone receptor, beta | 461 aa | 414 aa | 24.6 % |
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0.0764 | 0.5 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 0.1433 | 0.1433 |
Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0246 | 0.0246 |
Schistosoma mansoni | hypothetical protein | 0.0048 | 0.1545 | 0.2253 |
Schistosoma mansoni | survival motor neuron protein | 0.0048 | 0.1545 | 0.2253 |
Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.0045 | 0.1433 | 0.1433 |
Onchocerca volvulus | 0.0048 | 0.1545 | 0.5 | |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 0.1433 | 0.1433 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0246 | 0.0358 |
Echinococcus multilocularis | survival motor neuron protein 1 | 0.0233 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.212 | 0.1921 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.1433 | 0.209 |
Leishmania major | hypothetical protein, conserved | 0.003 | 0.0764 | 0.5 |
Toxoplasma gondii | LsmAD domain-containing protein | 0.003 | 0.0764 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0246 | 0.0358 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0764 | 0.5 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.1433 | 0.209 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0764 | 0.5 |
Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0019 | 0.0246 | 0.0246 |
Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.0045 | 0.1433 | 0.1217 |
Trypanosoma brucei | PAB1-binding protein , putative | 0.003 | 0.0764 | 0.5 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.212 | 0.1921 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1252 | 0.1032 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1252 | 0.1032 |
Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.0045 | 0.1433 | 0.209 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0246 | 0.0358 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.6857 | 1 |
Brugia malayi | hypothetical protein | 0.003 | 0.0764 | 0.0532 |
Loa Loa (eye worm) | hypothetical protein | 0.003 | 0.0764 | 0.0532 |
Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0246 | 0.0246 |
Brugia malayi | Iron-sulfur cluster assembly accessory protein | 0.0048 | 0.1545 | 0.1332 |
Echinococcus multilocularis | Mitotic checkpoint protein PRCC, C terminal | 0.0152 | 0.6301 | 0.6301 |
Trypanosoma cruzi | PAB1-binding protein , putative | 0.003 | 0.0764 | 0.5 |
Schistosoma mansoni | thyroid hormone receptor | 0.0164 | 0.6857 | 1 |
Echinococcus granulosus | Mitotic checkpoint protein PRCC C terminal | 0.0152 | 0.6301 | 0.6301 |
Schistosoma mansoni | hypothetical protein | 0.0152 | 0.6301 | 0.9189 |
Echinococcus multilocularis | thyroid hormone receptor alpha | 0.0164 | 0.6857 | 0.6857 |
Schistosoma mansoni | hypothetical protein | 0.0019 | 0.0246 | 0.0358 |
Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0019 | 0.0246 | 0.0246 |
Echinococcus granulosus | survival motor neuron protein 1 | 0.0233 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.212 | 0.1921 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1252 | 0.1826 |
Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.0045 | 0.1433 | 0.1433 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.212 | 0.1921 |
Brugia malayi | MH2 domain containing protein | 0.0144 | 0.5944 | 0.5841 |
Loa Loa (eye worm) | hypothetical protein | 0.0233 | 1 | 1 |
Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.0045 | 0.1433 | 0.1217 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.5944 | 0.5841 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0.0764 | 0.5 |
Echinococcus granulosus | GPCR family 2 | 0.0019 | 0.0246 | 0.0246 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.5944 | 0.5841 |
Brugia malayi | hypothetical protein | 0.002 | 0.0273 | 0.0028 |
Echinococcus multilocularis | GPCR, family 2 | 0.0019 | 0.0246 | 0.0246 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 1.9953 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 6.3096 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Potency (functional) | 11.2202 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 15.8489 um | PUBCHEM_BIOASSAY: Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (binding) | = 31.6228 um | PUBCHEM_BIOASSAY: qHTS Assay for Identification of Novel General Anesthetics. In this assay, a GABAergic mimetic model system, apoferritin and a profluorescent 1-aminoanthracene ligand (1-AMA), was used to construct a competitive binding assay for identification of novel general anesthetics (Class of assay: confirmatory) [Related pubchem assays: 2385 (Probe Development Summary for Identification of Novel General Anesthetics), 2323 (Validation apoferritin assay run on SigmaAldrich LOPAC1280 collection)] | ChEMBL. | No reference |
Potency (functional) | 32.6427 uM | PUBCHEM_BIOASSAY: Nrf2 qHTS screen for inhibitors. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID493153, AID493163, AID504648] | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PubChem BioAssay. qHTS Assay to Find Inhibitors of Pin1. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 35.4813 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of binding or entry into cells for Lassa Virus. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID463114, AID540249] | ChEMBL. | No reference |
Species name | Source | Reference | Is orphan |
---|---|---|---|
Homo sapiens | ChEMBL23 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.